Navigation Links
CONRAD to host HIV symposium at 2nd Annual Antivirals Congress
Date:11/5/2012

Arlington, VA CONRAD HIV and microbicides experts will be featured at the 2nd Annual Antivirals Congress organized by Elsevier publications. This year's conference is being held on November 11-13 at the Boston Marriott Cambridge. Executive and Scientific Director Gustavo Doncel and Director of Product Development David Friend will discuss ex vivo models for testing topical antiviral microbicides and current antiretroviral based microbicide products.

Other speakers at the CONRAD symposium include Tom Hope from Northwestern University and Patrick Kiser from the University of Utah who will speak on defining the interaction of HIV and the mucosal barriers exposed during sexual transmission, and novel microbicide dosage forms to prevent HIV transmission, respectively.

What: CONRAD Symposium: The Use of Antiviral Agents to Prevent HIV Transmission

When and Where: Monday, November 12th 2:00-3:40PM Boston Marriott Cambridge

CONRAD, a not for profit scientific organization based in Arlington, Virginia, specializes in developing new contraceptive methods and products to prevent or reduce HIV and other sexually transmitted infections. Several products in the pipeline focus on multi-purpose prevention options which provide contraception as well as HIV and STI protection. CONRAD tested and developed tenofovir gel, the first drug to show proof of concept that a vaginal gel containing antiretrovirals can reduce HIV and HSV-2 infections when used before and after sex.

Tenofovir is a drug commonly used by those infected with HIV to prevent the virus from multiplying in the immune system. A clinical study of women in South Africa who used a vaginal gel containing tenofovir has shown that it is 40-54 percent effective in reducing sexual transmission when used before and after sex.

The Antiretrovirals Congress provides state-of-the-art reports for scientists, health professionals and non governmental authorities to accelerate progress in the development and application of antivirals. The Congress serves as an interface between different interest groups from academia, those in research and development, regulatory and governmental agencies, charities, and health and industry professionals.


'/>"/>

Contact: Annette Larkin
alarkin@conrad.org
703-772-6427
CONRAD
Source:Eurekalert

Related medicine news :

1. Triple negative breast cancer symposium highlights current advances
2. John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium
3. Kessler Foundation scientists present cognitive research findings at MS dual symposium
4. fiteBac™ SkinCare, LLC Participates in OSAP Symposium on Infection Control
5. International symposium on veterinary rehabilitation and physical therapy to be held in Vienna
6. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
7. Symposium on sustainability to feature three new NJIT faculty
8. Key research from the 2012 Breast Cancer Symposium highlights treatment advances for early breast cancer
9. Leading stem cell scientists to focus on diabetes, eye diseases at Cedars-Sinai symposium
10. Penn Translational Medicine Institute to hold 7th Annual Symposium
11. International symposium will address non-Hodgkins lymphoma in the young
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... it’s been named Agency of Record (AOR) for Theravent, Inc. , the ... snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand distribution ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover ... O2X , an active lifestyle company that provides Human Performance Training and ... firefighters, police offers, first responders, military officers and others in service through the ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Alive for ... who wish to overcome their mental health struggles. The Alive team uses advanced ... says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... 21, 2017 , ... Northern California Medical Associates ... Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference plays ... an opportunity to learn about cutting edge treatments, to collaborate, share research and ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... practices, is seeking candidates to serve on its Accreditation and Standards Committees ... “RadSite’s ultimate mission is improving image quality and reducing patient radiation dose,” ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
Breaking Medicine Technology: